Neonatal Morbidities of Fetal Growth Restriction: Pathophysiology and Impact.
Malhotra A, Allison BJ, Castillo-Melendez M, Jenkin G, Polglase GR, Miller SL. · 2019
Read Neonatal Morbidities of Fetal Growth Restriction: Pathophysiology and Impact. by Malhotra A, Allison BJ, Castillo-Melendez M, Jenkin G, Polglase GR, Miller SL. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6374308.txt.
Introduction
Malhotra and co-authors present a review in Frontiers in Endocrinology on fetal growth restriction. In this pregnancy complication, a failing placenta starves the fetus of oxygen and nutrients. Affected babies face high risks around birth and lasting health deficits later in life.
The review explains how the fetus adapts its blood flow and organ growth before birth. Those adaptations set up many newborn problems after delivery. The authors go organ by organ through the main morbidities, with signs, diagnostic tools, and care strategies for each. They also survey targeted therapies now under study. The goal is earlier detection and better monitoring of at-risk newborns.
Catalog record
| CREATOR | Malhotra A, Allison BJ, Castillo-Melendez M, Jenkin G, Polglase GR, Miller SL. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 106 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Neonatal Morbidities of Fetal Growth Restriction: Pathophysiology and Impact By Atul Malhotra, Beth J. Allison, Margie Castillo-Melendez, Graham Jenkin, Graeme R. Polglase, Suzanne L. Miller Published in: Frontiers in Endocrinology DOI: 10.3389/fendo.2019.00055 ABSTRACT Being born small lays the foundation for short-term and long-term implications for life. Intrauterine or fetal growth restriction describes the pregnancy complication of pathological reduced fetal growth, leading to significant perinatal mortality and morbidity, and subsequent long-term deficits. Placental insufficiency is the principal cause of FGR, which in turn underlies a chronic undersupply of oxygen and nutrients to the fetus. The neonatal morbidities associated with FGR depend on the timing of onset of placental dysfunction and growth restriction, its severity, and the gestation at birth of the infant. In this review, we explore the pathophysiological mechanisms involved in the development of major neonatal morbidities in FGR, and their impact on the health of the infant. Fetal cardiovascular adaptation and altered organ development during gestation are principal contributors to postnatal consequences of FGR. Clinical presentation, diagnostic tools and management strategies of neonatal morbidities are presented. We also present information on the current status of targeted therapies. A better understanding of neonatal morbidities associated with FGR will enable early neonatal detection, monitoring and management of potential adverse outcomes in the newborn period and beyond. OVERVIEW AND DESCRIPTION Fetal growth restriction (FGR) describes the fetus that does not grow to its expected biological potential in utero, and is a relatively common complication of pregnancy. True FGR, as compared to constitutional smallness, is a pathological condition wherein the placental fails to deliver an adequate supply of oxygen and nutrients to the developing fetus, termed placental insufficiency. As a consequence, fetal growth becomes stunted. It is only in the last several years that consensus definitions for pathological FGR have been developed (1), but it remains that many cases of FGR in utero remain undetected, and therefore the neonatal description of small for gestational age (SGA) continues to be a useful and necessary proxy for FGR (2). Traditionally, an estimated fetal weight or abdominal circumference of less than the 10th centile for the population at a given gestational age was considered highly suggestive of FGR. However this broad description of SGA includes the many infants (~20%) that are born small, but are otherwise healthy (2). Accordingly, consensus definitions for FGR now incorporate Doppler indices of placental function/ dysfunction during pregnancy (1), to provide a more robust assessment of pathological fetal growth restriction. Clear and well-defined guidelines for description of FGR subsequent to placental insufficiency are important for two broad reasons, (i) early identification of FGR flags infants who are at significantly elevated risk for neonatal complications, and (ii) early identification of infants with FGR who would benefit from intervention(s) to improve outcomes. The etiology of many adverse consequences of FGR arise in utero from fetal hypoxia and nutrient deprivation secondary to placental dysfunction, with fetal hemodynamic adaptations in utero laying the foundation for altered organ structure and function in the neonatal period and beyond. ETIOLOGY AND UTEROPLACENTAL FACTORS The basic determinants of fetal growth are the individual's genetic makeup, nutrient availability from the mother, and environmental factors, coupled with the capacity of the placenta to adequately transfer nutrients and oxygen to the fetus, and endocrine modulation of these interactions (3, 4). Reduced fetal growth, and subsequent pathological FGR, can be caused by maternal factors (e.g., under nutrition, hypertension, preeclampsia), fetal (chromosomal abnormalities, multiple fetuses) or placental factors (5), however in the majority of cases, FGR results from placental dysfunction (6). Here, the term placental insufficiency is broadly used to describe reduced transfer of oxygen and nutrients to the fetus, with adverse effects on fetal development. Antecedents of placental insufficiency can include maternal malnutrition and hypertension, but in up to 60% of cases the placental insufficiency is idiopathic, wherein there is a physiological deficiency in the remodeling of uterine and placental spiral arteries resulting in restricted uteroplacental perfusion (7). Abnormalities in placental function provide a primary clinical indicator that transfer of oxygen and nutrients is suboptimal, and fetal growth may be adversely affected. In the fetus, placental insufficiency is characterized by preferential blood flow redistribution to the vital organs (brain, myocardium, and adrenal glands), while other organs, including the gastrointestinal tract, skin, and others may be deprived of sufficient blood flow. This fetal redistribution of blood flow occurs as a direct result of hypoxia, and can be detected as altered umbilical, uterine and/or middle cerebral artery Doppler flows (8). Large population studies of small but otherwise healthy infants at birth (Apgar ≥ 7 at 5 min of life) demonstrates that severely growth restricted infants at the third birth weight centile are indeed chronically hypoxic; umbilical vein median pO2 13 mmHg (FGR) versus 26 mmHg (normally grown infants), and median SaO2 16 vs. 55% respectively (9, 10). In addition to the fundamental roles of oxygen and glucose for development, fetal growth is dependent on a number of key anabolic hormones—placental, pancreatic, thyroid, adrenal and pituitary hormones—any disruption in these can also lead to FGR (11, 12). The insulin-like growth factors -I and -II (IGF-I and IGF-II) are both proposed to play central roles in normal fetal growth, stimulating fetal cell proliferation, differentiation, protein and glycogen synthesis, where these actions are mediated via their receptors and the IGF-binding proteins (IGFBPs). The two IGFs are detected in the fetal circulation in early gestation, and in particular it is noted that decreased serum IGF-1 is correlated with reduced fetal growth (3, 13). IGF-1 also has a central role in brain growth, white matter development and brain connectivity (14). Pregnancy-associated plasma protein-A (PAPP-A), secreted by the placental decidua, cleaves IGFBP-4, which in turn is a potent inhibitor of IGF bioactivity. Accordingly, low levels of PAPP-A in early pregnancy are linked with an increased risk for FGR, although the predictive value of this biomarker still remains poor (15). A recent study has investigated whether administration of IGF-1 into the amniotic fluid can improve postnatal growth and metabolism in a sheep model of FGR, and results from this study look promising (16) (see Interventions for Improved Outcomes section). Glucocorticoid hormones play a central role in the development and maturation of fetal organs, while growth hormone, which is the major hormonal regulator of postnatal growth, has no demonstrable effect on fetal growth per se (17). Exogenous glucocorticoids are administered to pregnant women at imminent risk of preterm birth to mature the fetal lungs, and preterm birth is a common complication of FGR. Preclinical and clinical evidence demonstrates that antenatal steroids may exacerbate growth restriction (particularly repeat doses) (18) and that the FGR fetus differentially responds to antenatal steroids compared to appropriately-grown fetuses, likely mediated via altered placental response to steroids (19). Antenatal glucocorticoids may not significantly improve neonatal outcomes in FGR preterm infants (20), and indeed, may have adverse effects on brain development (21, 22). Further research is clearly needed in this area. The fetus mounts a critical hemodynamic response to hypoxia, aimed at ensuring the most important fetal organs maximize their oxygen supply. This adaptive response redistributes blood flow away from peripheral vascular beds which is preferentially shunted toward essential organs, termed brain sparing (23). This results in preferential supply of